
SynAct (Q3 Update) - ADVANCE Approaching Full Recruitment

Redeye reviews SynAct Pharma's Q3 report. The ADVANCE study is progressing and on track to enrol all patients before year-end 2025. This means topline data will be available in H1 2026, a major catalyst. The company is funded into 2027.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

SynAct (Q3 Update) - ADVANCE Approaching Full Recruitment